A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).

@article{Limaye2013ARP,
  title={A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).},
  author={S. Limaye and S. Riley and Sihai Zhao and A. O'Neill and Marshall R. Posner and D. Adkins and Zachary Jaffa and J. Clark and R. Haddad},
  journal={Oral oncology},
  year={2013},
  volume={49 8},
  pages={
          835-41
        }
}
  • S. Limaye, S. Riley, +6 authors R. Haddad
  • Published 2013
  • Medicine
  • Oral oncology
  • OBJECTIVES There are limited chemotherapeutic options for advanced recurrent or metastatic SCCHN. The efficacy and toxicity of docetaxel with or without vandetanib was investigated in these patients. MATERIALS AND METHODS Patients with pathologically confirmed, recurrent or metastatic SCCHN who had progressed on platinum based therapy given as definitive or palliative treatment, were randomized in this open label, multicenter phase II study of docetaxel (75 mg/m2 IV Q3 weeks) with or without… CONTINUE READING
    42 Citations
    Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.
    • A. Colevas
    • Medicine
    • Journal of the National Comprehensive Cancer Network : JNCCN
    • 2015
    • 12
    • PDF

    References

    SHOWING 1-10 OF 31 REFERENCES
    Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
    • 121
    Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
    • 60
    Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
    • A. Dreyfuss, J. Clark, +7 authors M. Posner
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 226
    Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
    • J. Heymach, B. Johnson, +10 authors R. Herbst
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2007
    • 271
    Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
    • G. Catimel, J. Verweij, +7 authors S. Kaye
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 1994
    • 240
    Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
    • 266